Strongest evidence: High and moderate evidence strength outcomes include reduced pain (6 of 7 studies beneficial, predominantly small to moderate effect sizes), reduced systolic blood pressure (4 of 4 studies, moderate effect, with meta-analytic estimates of a 3.7 mmHg decrease), reduced interleukin-6 levels (4 of 6 studies beneficial, moderate effect, 1000 mg/day most studied), reduced complex regional pain syndrome (3 of 3 studies, small effect, 1 g daily), and reduced oxidative stress (3 of 4 studies beneficial, mixed effect sizes, 1000 mg/day). These findings are strongest in clinical populations—surgical patients, those with type 2 diabetes, or other specific conditions—and effects typically appear within weeks to 60 days.
Mixed or weaker evidence: Low strength evidence covers reduced mortality risk (1 of 5 studies beneficial, small effect, in COVID-19/sepsis populations), reduced tumor necrosis factor-alpha (2 of 5 studies beneficial, mainly in acute settings like septic shock), improved lung function (2 of 4 studies beneficial, mixed effects, only 1 statistically significant), reduced gingival index (2 of 3 studies beneficial, small effects, but neutral for vitamin C alone), reduced diastolic blood pressure (2 of 3 studies beneficial, large effect in heat-exposed workers but neutral in young healthy participants), and reduced length of hospital stay (0 of 3 studies beneficial, all neutral). These outcomes show inconsistent results, often due to small sample sizes, short durations, or specific population-dependent effects.
Effective dose patterns: Across outcomes with moderate-to-high evidence, a common dose range emerges: 1000 mg daily (1 g) for reducing IL-6, oxidative stress, and complex regional pain syndrome, while 500 mg/day was used in the single beneficial study for lung function. For pain, doses varied, with higher intravenous doses (300–600 mg/kg/day) showing benefit in cancer patients, and oral doses around 1 g daily in surgical contexts. No single dose fits all outcomes, but 1000 mg daily appears most frequently in clinical trials.
Population insights: The research predominantly involves clinical populations—surgical patients (e.g., total knee arthroplasty), those with type 2 diabetes, acute critical illness (sepsis, COVID-19), or specific conditions like sarcopenia or carpal tunnel syndrome. Effects in healthy individuals or those without underlying conditions are less studied, and the neutral results in young healthy participants for diastolic blood pressure and other outcomes suggest benefits may be more pronounced in populations with elevated baseline risk (e.g., high blood pressure, oxidative stress).
Notable caveats: Publication bias is a concern across many outcomes—null-result studies may be underreported, potentially overstating benefits. Many studies used vitamin C in combination with other ingredients (e.g., vitamin E, curcumin, hydrocortisone), making it difficult to isolate its effect. Sample sizes are often small, and study durations are short (e.g., median 4 days for mortality studies, 180 days for gingival index), limiting conclusions about long-term effects. Finally, the evidence base per outcome is small (3–7 studies), so all findings should be considered preliminary, especially for low-strength outcomes.